{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:41:34Z","timestamp":1788309694272,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-intensity glucocorticoid regimens are commonly used to induce and maintain remission in Juvenile Dermatomyositis but are associated with several adverse side-effects. Evidence-based treatment guidelines from North American and European pediatric rheumatology research societies both advocate induction with intravenous pulse steroids followed by high dose oral steroids (2\u2009mg\/kg\/day), which are then tapered. This study reports the time to disease control with reduced glucocorticoid dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the records at a single tertiary-care children\u2019s hospital of patients diagnosed with Juvenile Dermatomyositis between 2000 and 2014 who had a minimum of 2\u2009years of follow-up. The primary outcome measure was time to control of muscle and skin disease. Additional outcome measures included glucocorticoid dosing, effect of treatment on height, frequency of calcinosis, and complications from treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 69 patients followed during the study period, 31 fulfilled inclusion criteria. Median length of follow-up was 4.58\u2009years, (IQR 3\u20137.5). Myositis control was achieved in a median of 7.1\u2009months (IQR 0.9\u201363.4). Cutaneous disease control was achieved in a median of 16.7\u2009months (IQR 4.3\u201389.5). The median starting dose of glucocorticoids was 0.85\u2009mg\/kg\/day, (IQR 0.5\u20131.74). The median duration of steroid treatment was 9.1\u2009months, (IQR 4.7\u201317.4), while the median duration of any pharmacotherapy was 29.2\u2009months (IQR 10.4 to 121.3). Sustained disease control off medications was achieved in 21\/31 (68%) patients by the end of review. Persistent calcinosis was identified in only one patient (3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current accepted treatment paradigms for Juvenile Dermatomyositis include oral glucocorticoids beginning at 2\u2009mg\/kg\/day and reduced over a prolonged time period. However, our results suggest that treatment using reduced doses and duration with early use of steroid-sparing agents is comparably effective in achieving favorable outcomes in Juvenile Dermatomyositis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-021-00615-0","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T07:03:08Z","timestamp":1629183788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Favorable outcomes with reduced steroid use in juvenile dermatomyositis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-2402","authenticated-orcid":false,"given":"Amir B.","family":"Orandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lampros","family":"Fotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7543-7456","authenticated-orcid":false,"given":"Anthony R.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-0216","authenticated-orcid":false,"given":"Kevin W.","family":"Baszis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"issue":"3","key":"615_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/art.11122","volume":"49","author":"EP Mendez","year":"2003","unstructured":"Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases registry. Arthritis Rheum. 2003;49(3):300\u20135. https:\/\/doi.org\/10.1002\/art.11122.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"615_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/joim.12444","volume":"280","author":"LG Rider","year":"2016","unstructured":"Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280(1):24\u201338. https:\/\/doi.org\/10.1111\/joim.12444.","journal-title":"J Intern Med"},{"issue":"7","key":"615_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137. https:\/\/doi.org\/10.1056\/NEJM197502132920706.","journal-title":"N Engl J Med"},{"issue":"8","key":"615_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137. https:\/\/doi.org\/10.1056\/NEJM197502202920807.","journal-title":"N Engl J Med"},{"issue":"12","key":"615_CR5","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European league against rheumatism\/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271\u201382. https:\/\/doi.org\/10.1002\/art.40320.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"615_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-3476(64)80325-5","volume":"64","author":"S Bitnum","year":"1964","unstructured":"Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr. 1964;64(1):101\u201331. https:\/\/doi.org\/10.1016\/S0022-3476(64)80325-5.","journal-title":"J Pediatr"},{"issue":"1","key":"615_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/acr.20015","volume":"62","author":"A Ravelli","year":"2010","unstructured":"Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63\u201372. https:\/\/doi.org\/10.1002\/acr.20015.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2 Suppl","key":"615_CR8","first-page":"338","volume":"20","author":"JC Jacobs Jr","year":"1977","unstructured":"Jacobs JC Jr. Treatment of dermatomyositis. Arthritis Rheum. 1977;20(2 Suppl):338\u201341.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"615_CR9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1542\/peds.59.2.212","volume":"59","author":"JC Jacobs","year":"1977","unstructured":"Jacobs JC. Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics. 1977;59(2):212\u20138.","journal-title":"Pediatrics"},{"issue":"6","key":"615_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11926-005-0048-1","volume":"7","author":"A Huber","year":"2005","unstructured":"Huber A, Feldman BM. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep. 2005;7(6):441\u20136. https:\/\/doi.org\/10.1007\/s11926-005-0048-1.","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"615_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1346-8138.1986.tb02935.x","volume":"13","author":"A Hidano","year":"1986","unstructured":"Hidano A, Kaneko K, Arai Y, Kikuchi R. Survey of the prognosis for dermatomyositis, with special reference to its association with malignancy and pulmonary fibrosis. J Dermatol. 1986;13(4):233\u201341. https:\/\/doi.org\/10.1111\/j.1346-8138.1986.tb02935.x.","journal-title":"J Dermatol"},{"issue":"10019","key":"615_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(15)01021-1.","journal-title":"Lancet"},{"issue":"6","key":"615_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0022-3476(83)80706-9","volume":"103","author":"SL Bowyer","year":"1983","unstructured":"Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6):882\u20138. https:\/\/doi.org\/10.1016\/S0022-3476(83)80706-9.","journal-title":"J Pediatr"},{"issue":"6","key":"615_CR14","first-page":"R10-R","volume":"37","author":"AM Callen","year":"1994","unstructured":"Callen AM, Pachman LM, Hayford J, Chung A, Ramseygoldman R. Intermittent High-Dose Intravenous Methylprednisolone (Iv Pulse) Therapy Prevents Calcinosis and Shortens Disease Course in Juvenile Dermatomyositis (Jdms). Arthritis Rheum. 1994;37(6):R10-R.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"615_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","volume":"43","author":"AM Huber","year":"2000","unstructured":"Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541\u20139. https:\/\/doi.org\/10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"615_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1067\/mjd.2002.122196","volume":"47","author":"RE Fisler","year":"2002","unstructured":"Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505\u201311. https:\/\/doi.org\/10.1067\/mjd.2002.122196.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"615_CR17","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/art.24571","volume":"60","author":"S Kim","year":"2009","unstructured":"Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60(6):1825\u201330. https:\/\/doi.org\/10.1002\/art.24571.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"615_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3899\/jrheum.090953","volume":"37","author":"E Stringer","year":"2010","unstructured":"Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood arthritis and rheumatology research Alliance (CARRA) JDM treatment survey. J Rheumatol. 2010;37(9):1953\u201361. https:\/\/doi.org\/10.3899\/jrheum.090953.","journal-title":"J Rheumatol"},{"issue":"4","key":"615_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1090-3798(98)80021-4","volume":"2","author":"B Tabarki","year":"1998","unstructured":"Tabarki B, Ponsot G, Prieur AM, Tardieu M. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol. 1998;2(4):205\u201311. https:\/\/doi.org\/10.1016\/S1090-3798(98)80021-4.","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"615_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jpeds.2009.09.008","volume":"156","author":"DM Levy","year":"2010","unstructured":"Levy DM, Bingham CA, Kahn PJ, Eichenfield AH, Imundo LF. Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids. J Pediatr. 2010;156(2):302\u20137. https:\/\/doi.org\/10.1016\/j.jpeds.2009.09.008.","journal-title":"J Pediatr"},{"issue":"11","key":"615_CR21","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1002\/art.21378","volume":"52","author":"AV Ramanan","year":"2005","unstructured":"Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570\u20138. https:\/\/doi.org\/10.1002\/art.21378.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"615_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/acr.20071","volume":"62","author":"AM Huber","year":"2010","unstructured":"Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's arthritis and rheumatology research Alliance consensus conference. Arthritis Care Res (Hoboken). 2010;62(2):219\u201325. https:\/\/doi.org\/10.1002\/acr.20071.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"615_CR23","doi-asserted-by":"publisher","unstructured":"Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C, Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood arthritis and rheumatology research Alliance consensus conference. Arthritis Care Res (Hoboken) 2012;64(4):546\u2013553, DOI: https:\/\/doi.org\/10.1002\/acr.20695.","DOI":"10.1002\/acr.20695"},{"issue":"2","key":"615_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"F Bellutti Enders","year":"2017","unstructured":"Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209247.","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 68","key":"615_CR25","first-page":"S148","volume":"29","author":"A Ravelli","year":"2011","unstructured":"Ravelli A, Lattanzi B, Consolaro A, Martini A. Glucocorticoids in paediatric rheumatology. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S148\u201352.","journal-title":"Clin Exp Rheumatol"},{"key":"615_CR26","first-page":"1","volume":"314","author":"RJ Kuczmarski","year":"2000","unstructured":"Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States. Adv Data. 2000;314:1\u201327.","journal-title":"Adv Data"},{"issue":"9","key":"615_CR27","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/art.22856","volume":"56","author":"MA Cooper","year":"2007","unstructured":"Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107\u201311. https:\/\/doi.org\/10.1002\/art.22856.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"615_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314\u201324. https:\/\/doi.org\/10.1002\/art.37754.","journal-title":"Arthritis Rheum"},{"key":"615_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","volume":"184","author":"K Phillippi","year":"2017","unstructured":"Phillippi K, Hoeltzel M, Byun Robinson A, Kim S, Childhood A. Rheumatology research Alliance legacy registry I. race, income, and disease outcomes in juvenile dermatomyositis. J Pediatr. 2017;184:38\u201344 e1. https:\/\/doi.org\/10.1016\/j.jpeds.2017.01.046.","journal-title":"J Pediatr"},{"issue":"1","key":"615_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/03009742.2011.608376","volume":"41","author":"P Mathiesen","year":"2012","unstructured":"Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol. 2012;41(1):50\u20138. https:\/\/doi.org\/10.3109\/03009742.2011.608376.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"615_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12969-017-0199-4","volume":"15","author":"AB Orandi","year":"2017","unstructured":"Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF, subgroup CJM. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J. 2017;15(1):71.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"615_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11926-014-0467-y","volume":"16","author":"MF Hoeltzel","year":"2014","unstructured":"Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014;16(12):467. https:\/\/doi.org\/10.1007\/s11926-014-0467-y.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"615_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jpeds.2005.10.032","volume":"148","author":"LM Pachman","year":"2006","unstructured":"Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148(2):247\u201353. https:\/\/doi.org\/10.1016\/j.jpeds.2005.10.032.","journal-title":"J Pediatr"},{"issue":"7","key":"615_CR34","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/art.23829","volume":"59","author":"R Seshadri","year":"2008","unstructured":"Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008;59(7):989\u201395. https:\/\/doi.org\/10.1002\/art.23829.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"615_CR35","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0190-9622(84)80263-7","volume":"10","author":"TY Woo","year":"1984","unstructured":"Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10(4):592\u2013600. https:\/\/doi.org\/10.1016\/S0190-9622(84)80263-7.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"615_CR36","first-page":"1545","volume":"16","author":"NY Olson","year":"1989","unstructured":"Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16(12):1545\u20137.","journal-title":"J Rheumatol"},{"issue":"1","key":"615_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-016-0134-0","volume":"15","author":"S Kim","year":"2017","unstructured":"Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, et al. Childhood arthritis and rheumatology research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J. 2017;15(1):1. https:\/\/doi.org\/10.1186\/s12969-016-0134-0.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"615_CR38","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/acr.20269","volume":"62","author":"KA Rouster-Stevens","year":"2010","unstructured":"Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res. 2010;62(10):1446\u201351. https:\/\/doi.org\/10.1002\/acr.20269.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"615_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12969-017-0174-0","volume":"15","author":"CH Spencer","year":"2017","unstructured":"Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, et al. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood arthritis and rheumatology research Alliance in North America. Pediatr Rheumatol Online J. 2017;15(1):50. https:\/\/doi.org\/10.1186\/s12969-017-0174-0.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"615_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018;14(5):279\u201389. https:\/\/doi.org\/10.1038\/nrrheum.2018.42.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"615_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","volume":"80","author":"H Kim","year":"2021","unstructured":"Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2021;80(3):406\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218690.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00615-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00615-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00615-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T08:56:11Z","timestamp":1673081771000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00615-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00615-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-142233\/v1","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}